€22.00
0.90% today
L&S, Jul 03, 11:24 am CET
ISIN
DE000A2P4LJ5
Symbol
PSG
Index
Sector
Industry

Pharmasgp Holding Share price

€22.20
+0.20 0.91% 1M
-0.30 1.33% 6M
-0.30 1.33% YTD
-5.70 20.43% 1Y
-1.80 7.50% 3Y
-12.30 35.65% 5Y
-12.30 35.65% 10Y
Xetra, Closing price Tue, Jul 02 2024
+0.00 0.00%
ISIN
DE000A2P4LJ5
Symbol
PSG
Index
Sector
Industry

Key metrics

Market capitalization €266.18m
Enterprise Value €293.93m
PER (TTM) P/E ratio 14.70
EV/FCF (TTM) EV/FCF 12.55
EV/Sales (TTM) EV/Sales 2.74
P/S ratio (TTM) P/S ratio 2.48
P/B ratio (TTM) P/B ratio 5.96
Dividend yield 6.13%
Last dividend (FY24) €1.36
Sales growth (TTM) Sales growth 20.19%
Turnover (TTM) Turnover €107.29m
EBIT (operating result TTM) EBIT €26.35m
Free cash flow (TTM) Free cash flow €23.42m
Cash position €46.27m
EPS (TTM) EPS €1.51
P/E ratio expected 14.19
P/S ratio expected 2.41
EV/Sales expected 2.66
Show more

Is Pharmasgp Holding a top scorer stock according to the dividend, high growth investing or Leverman strategy?

As a free StocksGuide basic user, you can view the scores for all 6,954 shares worldwide.

Pharmasgp Holding Share analysis

Unlock Scores for Free

Analyst opinions

2 Analysts have issued a Pharmasgp Holding forecast:

2x Buy
100%

Analyst opinions

2 Analysts have issued a Pharmasgp Holding forecast:

Buy
100%

Financial data from Pharmasgp Holding

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '24
+/-
%
107 107
20% 20%
100%
- Direct costs 27 27
4% 4%
25%
81 81
27% 27%
75%
- Selling and administrative expenses 45 45
30% 30%
42%
- Research and development costs - -
-
-
36 36
23% 23%
33%
- Depreciation and amortization 9.39 9.39
1% 1%
9%
EBIT (operating result) EBIT 26 26
33% 33%
25%
Net profit 18 18
38% 38%
17%

Figures in millions EUR.

Don't miss a thing! We will send you all news about the Pharmasgp Holding share directly to your mailbox free of charge.

If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.

Pharmasgp Holding Share News

EQS
6 days ago
Die Kernmarken des Unternehmens decken chronische Indikationen ab, darunter rheumatische Schmerzen und Nervenschmerzen sowie andere altersbedingte Leiden. In Deutschland ist PharmaSGP mit den Markenfamilien RubaXX®bei rheumatischen Schmerzen und Restaxil®bei neuralgischen Schmerzen (auch: Nervens...
EQS
12 days ago
Die Kernmarken des Unternehmens decken chronische Indikationen ab, darunter rheumatische Schmerzen und Nervenschmerzen sowie andere altersbedingte Leiden. In Deutschland ist PharmaSGP mit den Markenfamilien RubaXX® bei rheumatischen Schmerzen und Restaxil® bei neuralgischen Schmerzen (auch: Nerve...
EQS
about 2 months ago
Die Kernmarken des Unternehmens decken chronische Indikationen ab, darunter rheumatische Schmerzen und Nervenschmerzen sowie andere altersbedingte Leiden. In Deutschland ist PharmaSGP mit den Markenfamilien RubaXX® bei rheumatischen Schmerzen und Restaxil® bei neuralgischen Schmerzen (auch: Nerve...
More Pharmasgp Holding News

Company profile

PharmaSGP Holding SE engages in the manufacture of non-chemical, over-the-counter pharmaceutical products. Its product brands include RubaXX, Restaxil, FULMINAN, DESEO, Neradin, and TAUMEA. The company is headquartered in Gräfelfing, Germany.

Head office Germany
CEO Natalie Weigand
Employees 89
Founded 2012
Website pharmasgp.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today